Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Drug mix shrinks colon cancer tumors in 39% of patients: Study

by Reuters

Sep 20, 2021 - 5:40 pm GMT+3
A laboratory technician holds blood pressure tablets during quality checks in the laboratories at the Merck headquarters in Darmstadt, Germany, June 25, 2014. (Getty Images)
A laboratory technician holds blood pressure tablets during quality checks in the laboratories at the Merck headquarters in Darmstadt, Germany, June 25, 2014. (Getty Images)
by Reuters Sep 20, 2021 5:40 pm
RECOMMENDED
UAE astronaut Sultan AlNeyadi arrives for a news conference at the Museum of the Future in the Gulf emirate of Dubai, on Feb. 2, 2023. (AFP Photo)

Emirati 'Sultan of Space' mulls fasting on ISS during Ramadan

International-Space-Station

A combination of a previously existing cancer drug, Erbitux, and Mirati Therapeutics Inc's genetic mutation-targeting adagrasib have managed to shrink tumors in 39% of patients with advanced colorectal cancer in a small trial, the company said Sunday.

Chief Executive Officer Charles Baum told Reuters that Mirati plans to meet with the U.S. Food and Drug Administration in October to discuss whether it can pursue accelerated approval based on the combination therapy data.

Adagrasib targets a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumor cancers.

Like other newer experimental drugs, it homes in on specific gene mutations driving cancer regardless of the organ in which the disease originated.

In May, Amgen Inc's Lumakras became the first approved drug in the class after the U.S. Food and Drug Administration cleared it for use in patients with advanced non-small cell lung cancer.

At a meeting of the European Society of Medical Oncology (ESMO) on Sunday, Mirati said that out of 28 evaluated trial patients treated with adagrasib plus Erbitux, 11, or 39%, experienced tumor shrinkage. Two patients had tumor growth, but the cancer was stabilized in the others, Mirati said.

Erbitux is an Eli Lilly & Co. drug designed to block one of the signals that tells a tumor cell to grow by attaching to a structure on the cell called the epidermal growth factor receptor (EGFR).

At the ESMO meeting earlier this week, Amgen said a trial of Lumakras in combination with its own EGFR inhibitor Vectibix found that 7 out of 26 advanced colorectal cancer patients, or 27%, responded to the combination therapy.

Mirati said that at the time of its analysis, with a median follow-up of seven months, 63% of enrolled patients remained on its combination treatment.

In a segment of the trial where colorectal cancer patients were given adagrasib alone, 22% of evaluated patients responded to the drug, the company said.

Researchers said serious side effects occurred in 30% of patients treated with adagrasib alone, and in 16% of patients treated with the combination. Two patients who received the combination discontinued treatment after developing infusion-related reactions.

"It looks like we've gained quite a bit in efficacy and not really added much significant toxicity. So that's why, you know, that combination approach may end up being our fastest approach for accelerated approval," CEO Baum said.

Mirati plans to present updated results from a trial of adagrasib for lung cancer patients at ESMO on Monday.

Both Amgen and Mirati are also studying their drugs in combination with Keytruda, Merck & Co.’s blockbuster immunotherapy, for treating lung cancer.

RECOMMENDED
UAE astronaut Sultan AlNeyadi arrives for a news conference at the Museum of the Future in the Gulf emirate of Dubai, on Feb. 2, 2023. (AFP Photo)

Emirati 'Sultan of Space' mulls fasting on ISS during Ramadan

International-Space-Station
  • shortlink copied
  • RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    cancer treatment cancer research drugs treatment colon cancer
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    A Turkish police officer stands guard in front of the closed Dutch Consulate in Istanbul, Türkiye, Feb. 1, 2023. (Reuters Photo)

    Türkiye angered over 'intentional' closure of foreign missions

    türkiye-eu-relations
    A Kangal dog and a lamb are seen in Elazığ, eastern Türkiye, Feb. 3, 2023. (IHA Photo)

    Turkish Kangal dog embraces role of mother to lamb

    KANGAL-DOG

    Over 200 flights cancelled in Istanbul due to expected snowstorm

    snowstorm

    'All of Ukraine will burn' due to US supplies: Russia's Medvedev

    Russian-invasion-of-Ukraine
    No Image
    Lebanon marks anniversary of Beirut blast, still in ruins
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021